



CooperCompanies

Investor Presentation

January 10, 2022

CooperVision® CooperSurgical®



Cautionary Statements

Forward-Looking Statements

This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements of which are other than statements of historical fact, including all statements regarding the expected impact of the ongoing COVID-19 pandemic on our business; and statements regarding acquisitions including the acquired companies' financial position, market position, product development and business strategy, expected cost synergies, expected timing and benefits of the transaction, difficulties in integrating entities or operations, as well as estimates of our and the acquired entities' future expenses, sales and diluted earnings per share are forward-looking. In addition, all statements regarding anticipated growth in our revenue, anticipated effects of any product recalls, anticipated market conditions, planned product launches and expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like "believes," "outlook," "probable," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties.

Detailed descriptions of a number of important risk factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements can be found in our Securities and Exchange Commission filings, including under the "Forward-Looking Statements" section in our press releases and under the "Business", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in our most recent Annual Report on Form 10-K, as such sections may be updated in our Quarterly Reports on Form 10-Q, copies of which are available on the Company's website: www.cooperkos.com. We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.

Non-GAAP Financial Measures

Certain financial measures included in this presentation, or which may be referred to in management's discussion of the Company's results and outlook, are non-GAAP measures that we believe are helpful in understanding our results, for example, constant currency, adjusted EBITDA, non-GAAP earnings per share and non-GAAP margin results. The non-GAAP measures exclude costs which we generally would not have otherwise incurred in the periods presented as a part of our continuing operations. Our non-GAAP financial results are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. The reasons that we use these non-GAAP measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are available in our Securities and Exchange Commission filings, including under the "Reconciliation of GAAP Results to Non-GAAP Results" section in our press releases and under the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, copies of which are available on the Company's website: www.cooperkos.com.

A Leading Medical Device Company



Improving lives one person at a time

Industry-leader in
Vision and
Women's Health

Member of the
S&P 500 since
2016



FY21 Revenue \$2.92B




12,000+
Global
Workforce

10+
Manufacturing and
Distribution Sites

100+
Countries Where
Cooper Products
Are Sold

CooperCompanies

8.2% annual sales growth from 2016 to 2021



CooperCompanies

Fiscal 2022 financial guidance

		FY22 Guidance*	Growth vs. FY21
Sales	Total	\$3,032 - \$3,090	6% - 8% cc
	CooperVision	\$2,225 - \$2,267	6% - 8% cc
	CooperSurgical	\$807 - \$823	6% - 8% cc
EPS	Non-GAAP	\$13.60 - \$14.00	9.5% - 12.5% cc




CooperVision

A global leader dedicated to helping improve the way people see each day




Global Soft Contact Lens Market

Market by Competitor



Market by Category



High Barriers to Entry

- High capital outlay with highly specialized manufacturing
- Technological know-how
- Stringent FDA and worldwide regulation
- Long history of product innovation (SiHy with intellectual property)

Favorable Industry Characteristics


- Strong fundamental growth drivers
- Underlying wearer growth
- Limited reimbursement risk
- Recession resistant
- Annuity business (stickiness)



The Growing Myopia Epidemic

Myopia is expected to affect half the world population by 2050

Worldwide Prevalence of Myopia



Why?



Increased screen time



Less time outdoors



Genetics

Risks

Significant ocular health issues

Impaired learning and development

Impact to quality of everyday life



Contact Lens Market Drivers

Strong fundamental growth drivers

- New fits/trade-up
 - Shift into 1 Day SiHy lenses
 - Growth in Torics and Multifocals
- Growing global wearer base
 - Growing prevalence of myopia
 - 1/3 of the world's population is myopic going to 1/2 by 2050
 - Geographic expansion – low emerging market penetration
- Higher net pricing



A Global Leader in Myopia Management

Broadest portfolio of science-based treatment options addressing the progression of myopia in children



MiSight[®] 1 day

BRILLIANT FUTURES™
WITH MISIGHT[®] 1 day

**Only FDA approved
myopia control product**



Ortho-k



Paragon




Procornea



GP Specialists

**Broad range of market-
leading Ortho-k lenses**



SG

**SIGHTGLASS
VISION**

**Innovative myopia
management spectacles**



CooperCompanies

MiSight[®] 1 day

First and only FDA-approved⁽¹⁾ myopia control contact lens

Business Highlights

- Launching Brilliant Futures™ Myopia Management Program with MiSight[®] in multiple countries worldwide including the U.S.
- Sold as a treatment program by practitioners
- Investing in myopia management globally including in MiSight[®]
- Received regulatory approval in China

Growth Drivers⁽³⁾

- Works for nearly all myopic children
- Cuts myopia progression by roughly 59% on average⁽²⁾
- Works at any age a child starts treatment
- Works for as long as the child wears it
- There is no rebound if treatment is stopped



Note: (1) MiSight[®] (omafilcon A) daily wear single use Soft Contact Lenses are indicated for the correction of myopic ametropia and for slowing the progression of myopia (nearsightedness) in children with non-diseased eyes, who at the initiation of use are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal. (2) When compared to the children in the control group wearing a single vision 1-day contact lens. (3) As confirmed by our industry-leading, 7-year clinical study of MiSight[®].




CooperVision

History of success

Durable Sales Growth



Outpacing Market Growth




CooperVision


Revenue by product category and geography

FY21 Revenue \$2.15B

Revenue by Category



Revenue by Geography



CooperVision

Well positioned to succeed

Products



Diverse suite of best-in-class products to fit a wide range of patient needs

1 Day

FRP

Sphere

Toric

Multifocal

Toric Multifocal

Extended Ranges

Myopia Management

Specialty

Silicone Hydrogel

Hydrogel

Support



Branded and customized solutions

Logistical and distribution excellence

Differentiated Value-Added Services



BRILLIANT FUTURES™
WITH MISOFT® 1 day

Relationships



Global footprint



Strong key account relationships

Outstanding customer experience



CooperSurgical


Healthy women, babies and families™



CooperSurgical®

FY21 Revenue \$771M

Revenue by Category



Paragard™
intrauterine copper contraceptive



endosee™ ADVANCE



INSORB™ Skin Stapler
Absorbable | Subcuticular



CooperCompanies

CooperSurgical

Fertility portfolio well positioned for success

Business Highlights

- Broadest medical device coverage of the entire IVF cycle⁽¹⁾
- Pioneers in IVF genetic testing (state-of-the-art R&D lab)
- Recently closed Generate Life Science acquisition (12/17/21)
 - Enables new strategic growth opportunities – egg & sperm donation, cryopreservation
 - Increases product offerings, leverages sales force

Fertility Industry Highlights

\$1.8B+


Global Market¹

5-10%

Annual Growth

- **Growth Drivers:**
 - Increasing maternal age
 - Greater access to treatment
 - Increased patient awareness/comfort
 - Greater worldwide disposable income
- **Up to 1 in 8 couples suffer from infertility worldwide**

Medical Devices for the IVF Cycle⁽¹⁾



CooperSurgical

Extensive office and surgical platform

Business Highlights

- Produce over 600 clinically-relevant medical devices used by women's health care providers in gynecology and obstetrics
- Recently closed Generate Life Science acquisition (12/17/21)
 - Expands CSI Labor & Delivery
 - Adds a well-established cord blood and cord tissue storage platform
 - Leverages CSI's highly-respected clinical/professional relationships to cross-sell and advance education
 - Solid recurring revenue stream

Industry Highlights

- **Medical Device Drivers:**
 - Shifting to minimally invasive procedures
 - Reimbursement is designed to drive procedures to the office
 - Health systems are looking for partnership relationship with vendors
- **Cord Blood and Cord Tissue Storage Drivers:**
 - Advancing stem cell research & therapies increase potential value of storage
 - Cord blood is standard of care alternative to bone marrow transplants for blood disorders¹
 - Regenerative Medicine potential applications rapidly emerging (lung disease, sports injury, etc.) with 1k+ ongoing clinical studies²



endosee ADVANCE

Paragard[™]
intrauterine copper contraceptive



INSORB[®] Skin Stapler
Absorbable | Subcuticular

RUMPII SYSTEM



CooperCompanies

1. Chao, N. Selection of an umbilical cord blood graft for hematopoietic cell transplantation. In: UpToDate. Negrin, R (Ed), UpToDate, Waltham, MA. <https://www.statista.com/statistics/1088694/regenerative-medicine-clinical-trials-by-phase-and-therapy/> Accessed Nov 10, 2021

CooperSurgical


Office and surgical – Paragard IUD

Business Highlights

- Only US FDA-approved 100% Hormone Free Intrauterine Device (IUD)
- Over 99% effective
- One simple active ingredient – Copper
- Lasts up to 10 years with Immediate Reversibility
- In office placement
- Opportunity to create top of mind awareness

IUD Industry Highlights

 Paragard[®]
intrauterine copper contraceptive




Growth Drivers:

- Mid-single digit market growth
- Increased awareness and desire for a non-hormonal product
- 70% of women are concerned about hormones in birth control
- Opportunity to shift the U.S. market toward non-hormonal products



CooperSurgical

History of success



Socially and Environmentally Responsible

Committed to enhancing the health and wellness of people and communities locally and globally

Sustainability



Clean Energy



Resource Conservation



Commitment to Recycling



Environmental Certifications



CooperCompanies

Our Employees



CEO **ACTION** FOR DIVERSITY & INCLUSION



Giving and Community Involvement



OPTOMETRY
GIVINGSIGHT



Well Positioned for the Future

